Accelerating Your Gene Therapy To Patients: Not All Platforms Are Created Equal

The field of gene therapy manufacturing faces a significant hurdle in the form of a lack of process standardization. However, there are ways to address this challenge, such as using standardized methods, materials, analytics, and documentation. By implementing these measures, it is possible to minimize supply chain bottlenecks and increase manufacturing efficiencies and scalability. This, in turn, can lead to faster development timelines and smoother regulatory filings. In this fireside chat, George Buchman, Ph.D., Vice President, Pre-Clinical and Process Development, Catalent Cell & Gene Therapy and Thomas VanCott, Ph.D., Chief Scientific Officer, Combined Therapeutics, explore how a complete platform approach to fast-track AAVs can enhance quality and efficiency. This method can also help reduce manufacturing time while providing a well-suited process for late-stage clinical GMP production.